Dr. Mark Kotter’s bit.bio is at the forefront of a healthcare revolution, engineering precision cell therapies to transform lives and pave the way for a new generation of cures.
Dr Mark Kotter is a doctor with a vision for transforming lives through precision cell therapies. His mission is to empower biomedical innovation and pioneer a new generation of cures. In 2016, Kotter founded bit.bio, a pioneering biotech company based in Cambridge, UK that is reprogramming human cells to develop life-changing medical treatments.
Kotter was inspired to start bit.bio due to his clinical interest in helping patients with spinal cord injuries. He saw the potential for cell therapies to restore function for people with life-altering injuries. Under his leadership, bit.bio has raised over $200 million in funding and built a world-class team of experts in cell biology, biomedical engineering and regenerative medicine. The company has developed multiple cell products, disease models and partnerships that are driving revenue and enabling new discoveries.
Bit.bio’s biggest achievements to date include partnerships with global pharmaceutical companies, a long-term collaboration with contract research organization Charles River, and a team of over 180 employees at their Cambridge headquarters. Kotter and his team have built a cell therapy strategy focused on treating liver, immune and metabolic diseases. The future is bright for bit.bio as they work to develop clinical trials and bring novel treatments to patients in need.
Kotter’s vision, passion and perseverance in the face of biomedical challenges have led bit.bio to become a finalist for the 2023 Great British Entrepreneur Awards. Known as “The Grammys of Entrepreneurship,” the awards recognize inspirational leaders making an impact through innovation and business. Whether or not bit.bio takes home the top prize, Kotter and his team have already won by giving hope to patients and pioneering the future of medicine. To learn more about bit.bio and its work transforming lives through the engineering of human cells, visit www.bit.bio.